High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Federica Sora', Patrizia Chiusolo, Simona Sica, Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Giuseppe Leone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].
Lingua originaleEnglish
pagine (da-a)E133-E133
RivistaAmerican Journal of Hematology
Volume87
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • Chronic Lymphocytic Leukemia

Fingerprint Entra nei temi di ricerca di 'High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia'. Insieme formano una fingerprint unica.

Cita questo